Vanda Pharmaceuticals has launched NEREUS™ (tradipitant), the first new prescription drug in over 40 years for preventing motion sickness-induced vomiting in adults. Approved by the FDA in December 2025, NEREUS™ works by blocking NK-1 receptors in the brain to stop vomiting triggered by motion. It is available nationwide through pharmacies and a direct-to-consumer platform at nereus.us, priced at $85 per dose via the portal, significantly lower than the standard $255 list price. This new treatment offers a modern solution for millions of Americans affected by motion sickness during travel by car, plane, or boat.
Intertape Polymer Corp (IPG) has introduced a new PCR Air Pillow Film made with 50% recycled materials, including 35% post-consumer recycled content. This high-performance packaging film is designed to help companies meet sustainability goals without...
The global infant heart monitor market, valued at $2.83 billion in 2025, is projected to grow to $7.93 billion by 2035 at a CAGR of 10.85%. Growth is fueled by advances in wearable and wireless monitoring technologies, increased adoption of home care...
The European Commission has approved TEPKINLY (epcoritamab) combined with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma in adults. This marks the first bispecific antibody-based therapy authorized in Europe for se...
Halper Sadeh LLC is investigating whether shareholders of Arcosa, Bio-Techne, Iridium Communications, and LCI Industries are receiving fair deals in their companies' recent sales. The law firm suspects insiders may gain financial benefits not availab...
Law Offices of Howard G. Smith has announced upcoming deadlines for investors to file lead plaintiff motions in class action lawsuits against BitGo Holdings, Via Transportation, Zillow Group, and ADMA Biologics. These lawsuits allege that the compani...
